specific manufacturers exist for approved vaccines with adjuvants

Dynavax Technologies is a commercial-stage biopharmaceutical company specializing in the development and commercialization of novel vaccines using its proprietary Toll-like receptor 9 (TLR9) agonist adjuvant, CpG 1018. The company's flagship product, HEPLISAV-B, is the first and only two-dose hepatitis B vaccine for adults approved in the United States and Europe, offering higher protection rates than traditional three-dose regimens. Beyond its internal pipeline, Dynavax leverages its adjuvant technology through global partnerships to develop vaccines for indications such as COVID-19, pertussis, and shingles. The company maintains a specialized manufacturing facility in Germany and is a key player in the specialized field of adjuvanted vaccine immunology.